Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $26.7 million.

  • Foghorn Therapeutics' Operating Expenses fell 1581.17% to $26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.0 million, marking a year-over-year decrease of 1435.93%. This contributed to the annual value of $125.3 million for FY2024, which is 1180.9% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Operating Expenses stood at $26.7 million for Q3 2025, which was down 1581.17% from $28.7 million recorded in Q2 2025.
  • Foghorn Therapeutics' Operating Expenses' 5-year high stood at $38.6 million during Q1 2023, with a 5-year trough of $23.4 million in Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $31.7 million (2024), whereas its average is $31.0 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 7062.08% in 2021, then crashed by 1581.17% in 2025.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Operating Expenses stood at $28.8 million in 2021, then increased by 25.26% to $36.1 million in 2022, then dropped by 13.43% to $31.2 million in 2023, then decreased by 13.98% to $26.9 million in 2024, then fell by 0.77% to $26.7 million in 2025.
  • Its last three reported values are $26.7 million in Q3 2025, $28.7 million for Q2 2025, and $28.9 million during Q1 2025.